A Fresh Look at Arcellx (ACLX) Valuation Following Analyst Confidence in Clinical Progress

Simply Wall St.

Oct 29, 2025

Arcellx (ACLX) is drawing renewed interest following progress in studies targeting autoimmune diseases and multiple myeloma. Several analysts have recently reaffirmed their buy ratings and highlighted...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579970927"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579970927\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579970927?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-10-29 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579970927","market":"sg","top_or_hot":-1,"title":"A Fresh Look at Arcellx (ACLX) Valuation Following Analyst Confidence in Clinical Progress","media":"Simply Wall St.","content":"<div>\n<p>Arcellx (ACLX) is drawing renewed interest following progress in studies targeting autoimmune diseases and multiple myeloma. Several analysts have recently reaffirmed their buy ratings and highlighted...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/a-fresh-look-at-arcellx-aclx-valuation-following-analyst-con\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Fresh Look at Arcellx (ACLX) Valuation Following Analyst Confidence in Clinical Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Fresh Look at Arcellx (ACLX) Valuation Following Analyst Confidence in Clinical Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-29 18:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/a-fresh-look-at-arcellx-aclx-valuation-following-analyst-con><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arcellx (ACLX) is drawing renewed interest following progress in studies targeting autoimmune diseases and multiple myeloma. Several analysts have recently reaffirmed their buy ratings and highlighted...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/a-fresh-look-at-arcellx-aclx-valuation-following-analyst-con\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRGS","symbol_name":"Progress Software Corporation","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/a-fresh-look-at-arcellx-aclx-valuation-following-analyst-con","article_id":"2579970927","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aclx/arcellx/news/a-fresh-look-at-arcellx-aclx-valuation-following-analyst-con","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2579970927","pubTimestamp":1761733316,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Arcellx (ACLX) is drawing renewed interest following progress in studies targeting autoimmune diseases and multiple myeloma. Several analysts have recently reaffirmed their buy ratings and highlighted encouraging clinical outcomes.\nSee our latest analysis for Arcellx.\nMomentum has been building for Arcellx, with a 22% share price return over the last three months and a nearly 10% gain in the past month as positive clinical updates boost investor sentiment. While the company’s 1-year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRGS":"Progress Software Corporation","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4139":"生物科技","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4097":"系统软件","BK1167":"电子制造服务","ACLX":"ARCELLX, INC.","01967":"信恳智能"},"translate_title":"分析师对临床进展充满信心后重新审视Arcellx(ACLX)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"ACLX":1.5,"PRGS":1.5,"01967":1.5},"content_text":"Arcellx (ACLX) is drawing renewed interest following progress in studies targeting autoimmune diseases and multiple myeloma. Several analysts have recently reaffirmed their buy ratings and highlighted encouraging clinical outcomes. See our latest analysis for Arcellx. Momentum has been building for Arcellx, with a 22% share price return over the last three months and a nearly 10% gain in the past month as positive clinical updates boost investor sentiment. While the company’s 1-year total shareholder return is flat, its impressive 279% total return over the past three years reflects strong long-term value creation. If you’re following breakthroughs in biotech, this is a great time to explore more opportunities with our See the full list for free. With the stock’s impressive recent run and optimistic analyst sentiment, the question remains: does Arcellx have more upside ahead for investors, or has the market already priced in the company’s future growth potential? AdvertisementPrice-to-Book Ratio of 12.4x: Is it justified? Arcellx’s shares trade at a price-to-book ratio of 12.4x, slightly undercutting the peer average of 12.8x. This still significantly exceeds the biotech industry average of just 2.5x. At yesterday’s close of $87.49, this multiple suggests the stock is valued similarly to its closest peers, but remains notably expensive when compared to the overall sector. The price-to-book ratio measures how much investors are paying for each dollar of net assets on the company’s balance sheet. For an unprofitable biotech such as Arcellx, which is focused on a long research and development runway rather than near-term profits, the market tends to price in potential future breakthroughs and pipeline value that current book equity does not capture. This relatively high multiple may reflect investor optimism about Arcellx’s growth prospects and the perceived quality of its clinical pipeline. However, the fact that the ratio remains near peer levels but is much higher than the broader industry signals that the market is pricing in higher expectations for future value creation. If comparable companies are re-rated lower, Arcellx's valuation could also face pressure in the future. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book Ratio of 12.4x (ABOUT RIGHT) However, setbacks in clinical trials or a sudden shift in biotech sector sentiment could quickly reduce Arcellx's current momentum with investors. Find out about the key risks to this Arcellx narrative. Another View: Discounted Cash Flow Suggests Significant Undervaluation Looking at Arcellx from another angle, the SWS DCF model estimates its fair value at $550.82, which is far above the recent share price of $87.49. This suggests the market might be substantially underestimating the company's future cash flow potential. Can a DCF-driven outlook hold up against current market caution? Look into how the SWS DCF model arrives at its fair value. ACLX Discounted Cash Flow as at Oct 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Arcellx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Arcellx Narrative If you see the story differently or want to dive into the numbers yourself, it's easy to build your own perspective in just a few minutes. Do it your way A great starting point for your Arcellx research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Looking for more standout investment opportunities? Don't let the biggest winners pass you by. The smartest investors scan widely for fresh trends, hidden gems, and untapped value before they take off. Get ahead now using these handpicked strategies:  Target real income potential by zeroing in on companies offering strong yields and steady growth via these 21 dividend stocks with yields > 3%. Catalyze your portfolio with rapid growth ideas by joining the surge in innovation through these 26 AI penny stocks. Uncover valuable bargains the market has overlooked by jumping on these 869 undervalued stocks based on cash flows before the crowd notices.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}